EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients

Stella Pearson, Rognvald Blance, Fei Yan, Ya-Ching Hsieh, Bethany Geary, Fabio M R Amaral, Tim C P Somervaille, Kristina Kirschner, Anthony D Whetton, Andrew Pierce iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0286412 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Stella Pearson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Myeloproliferative Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Blood Cancer UK, Leukemia UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myelofibrosis is a myeloproliferative neoplasm (MPN) which typically results in reduced length and quality of life due to systemic symptoms and blood count changes arising from fibrotic changes in the bone marrow. While the JAK2 inhibitor ruxolitinib provides some clinical benefit, there remains a substantial unmet need for novel targeted therapies to better modify the disease process or eradicate the cells at the heart of myelofibrosis pathology. Repurposing drugs bypasses many of the hurdles present in drug development, such as toxicity and pharmacodynamic profiling. To this end we undertook a re-analysis of our pre-existing proteomic data sets to identify perturbed biochemical pathways and their associated drugs/inhibitors to potentially target the cells driving myelofibrosis. This approach identified CBL0137 as a candidate for targeting Jak2 mutation-driven malignancies. CBL0137 is a drug derived from curaxin targeting the Facilitates Chromatin Transcription (FACT) complex. It is reported to trap the FACT complex on chromatin thereby activating p53 and inhibiting NF-kB activity. We therefore assessed the activity of CBL0137 in primary patient samples and murine models of Jak2 -mutated MPN and found it preferentially targets CD34+ stem and progenitor cells from myelofibrosis patients by comparison with healthy control cells. Further we investigate its mechanism of action in primary haemopoietic progenitor cells and demonstrate its ability to reduce splenomegaly and reticulocyte number in a transgenic murine model of myeloproliferative neoplasms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisMyeloproliferative DisordersHumansMiceAnimalsProteomicsQuality of LifeJanus Kinase 2ChromatinMutation

Substanzen

Janus Kinase 2ChromatinJAK2 protein, human

Autor:innen und Institutionen

  • Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
  • School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Stoller Biomarker Discovery Centre, University of Manchester, Manchester, United Kingdom.
  • Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, Manchester, United Kingdom.

ORCID-Profile: Andrew Pierce

Förderung

  • Cancer Research UK
  • Blood Cancer UK
  • Leukemia UK
  • CRUK Scotland Centre funding

Zitieren

APA

Pearson, S., Blance, R., Yan, F., Hsieh, Y. C., Geary, B., Amaral, F. M. R., Somervaille, T. C. P., Kirschner, K., Whetton, A. D., & Pierce, A. (2023). Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0286412

Vancouver

Pearson S, Blance R, Yan F, Hsieh YC, Geary B, Amaral FMR, et al. Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients. PLOS ONE. 2023. doi:10.1371/journal.pone.0286412

BibTeX
@article{Pearson2023,
  author = {Pearson, Stella and Blance, Rognvald and Yan, Fei and Hsieh, Ya-Ching and Geary, Bethany and Amaral, Fabio M R and Somervaille, Tim C P and Kirschner, Kristina and Whetton, Anthony D and Pierce, Andrew},
  title = {Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0286412}
}
Kostenlos starten →